AKAukje L. Kreuger

Aukje L. Kreuger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aukje L. Kreuger has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia

    by Loes. L. Cornelissen, Aukje L. Kreuger, Camila Caram‐Deelder, Menno V. Huisman, Rutger A. Middelburg, Jean Louis H. Kerkhoffs, Peter A. von Dem Borne, Erik A. M. Beckers, Karen M. K. de Vooght, Jürgen Kuball, et al.

    Background: Intracranial hemorrhage is seen more frequently in acute leukemia patients compared to the general population. Besides leukemia‐related risk factors, also risk factors that are present in the general population might contribute to hemorrhagic complications in leukemia patients. Of those, cardiovascular risk factors leading to chronic vascular damage could modulate the occurrence of intracranial hemorrhage in these patients, as during their disease and treatment acute endothelial damage occurs due to factors like thrombocytopenia and inflammation.Objectives: Our aim was to explore if cardiovascular risk factors can predict intracranial hemorrhage in acute leukemia patients.Methods: In a case‐control study nested in a cohort of acute leukemia patients, including 17 cases with intracranial hemorrhage and 55 matched control patients without intracranial hemorrhage, data on cardiovascular risk factors were collected for all patients. Analyses were performed via conditional logistic regression.Results: Pre‐existing hypertension and ischemic heart disease in the medical history were associated with intracranial hemorrhage, with an incidence rate ratio of 12.9 (95% confidence interval [CI] 1.5 to 109.2) and 12.1 (95% CI 1.3 to110.7), respectively.Conclusion: Both pre‐existing hypertension and ischemic heart disease seem to be strong predictors of an increased risk for intracranial hemorrhage in leukemia patients.


  • Open Access

    Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study

    by Loes L. Cornelissen, Aukje L. Kreuger, Camila Caram-Deelder, Rutger A. Middelburg, Jean Louis H. Kerkhoffs, Peter A. von Dem Borne, Erik A. M. Beckers, Karen M. K. de Vooght, Jürgen Kuball, J. J. Zwaginga, et al.

    We designed a study to describe the incidence of intracranial hemorrhage according to severity and duration of thrombocytopenia and to quantify the associations of platelet transfusions with intracranial hemorrhage in patients with acute leukemia. In this case-control study nested in a cohort of 859 leukemia patients, cases (n = 17) were patients diagnosed with intracranial hemorrhage who were matched with control patients (n = 55). We documented platelet counts and transfusions for seven days before the intracranial hemorrhage in cases and in a “matched” week for control patients. Three measures of platelet count exposure were assessed in four potentially important time periods before hemorrhage. Among these leukemia patients, we observed the cumulative incidence of intracranial hemorrhage of 3.5%. Low platelet counts were, especially in the three to seven days preceding intracranial hemorrhage, associated with the incidence of intracranial hemorrhage, although with wide confidence intervals. Platelet transfusions during the week preceding the hemorrhage were associated with higher incidences of intracranial hemorrhage; rate ratios (95% confidence interval) for one or two platelet transfusions and for more than two transfusions compared with none were 4.04 (0.73 to 22.27) and 8.91 (1.53 to 51.73) respectively. Thus, among acute leukemia patients, the risk of intracranial hemorrhage was higher among patients with low platelet counts and after receiving more platelet transfusions. Especially, the latter is likely due to clinical factors leading to increased transfusion needs.


  • Open Access

    Ensuring HLA‐matched platelet support requires an ethnic diverse donor population

    by Aukje L. Kreuger, Geert W. Haasnoot, Judith A.E. Somers, Bert Tomson, Johanna G. van der Bon, Marian G.J. van Kraaij, Claudia M. Weller

    BACKGROUND: Patients refractory for platelet transfusions benefit from human leukocyte antigen (HLA)‐matched platelet transfusions. Differences in ethnic background of patients and donors could hamper the availability of sufficient numbers of HLA‐matched donors for all patients. We evaluated our HLA‐matched donor program and explored the role of ethnic background of patients related to the number of available donors.METHODS: We performed a cohort study among consecutive patients who received HLA‐matched platelet concentrates in the Netherlands between 1994 and 2017. The number of available matched donors was determined per patient. Haplotypes were constructed from genotypes with computer software (PyPop). Based on haplotypes, HaploStats, an algorithm from the National Marrow Donor Program, was used to assess the most likely ethnic background for patients with 5 or fewer and 30 or more donors.RESULTS: HLA typing was available for 19,478 donors in September 2017. A total of 1206 patients received 12,350 HLA‐matched transfusions. A median of 83 (interquartile range, 18‐266) donors were available per patient. For 95 (10.3%) patients, 5 or fewer donors were available. These patients were more likely to have an African American background, whereas patients with 30 or more donors were more often from Caucasian origin, compared with Caucasian origin for patients with 30 donors.CONCLUSION: Adequate transfusion support could be guaranteed for most but not all refractory patients. More non‐Caucasian donors are required to ensure the availability of HLA‐matched donors for all patients in the Netherlands.


  • HLA‐matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening

    by Aukje L. Kreuger, Anja B.U. Mäkelburg, Judith A.E. Somers, Bert Tomson, Leo M. G. van de Watering, Johanna G. van der Bom, Marian G.J. van Kraaij, Claudia M. Weller

    BACKGROUND: Recipients of platelet transfusions with 1‐hour corrected count increments (1hCCIs) of 7.5 or less on two subsequent platelet transfusions with random platelets may benefit from human leukocyte antigen (HLA)‐matched platelet concentrates. We aimed to quantify the efficacy of HLA‐matched platelets concentrates expressed in 1hCCIs.METHODS: We performed a cohort study among consecutive refractory patients who received HLA‐matched platelet concentrates in the Netherlands between 1994 and 2017. We performed mixed‐model linear regression comparing 1hCCIs after HLA split‐antigen–matched transfusions with 1hCCIs after HLA‐mismatched transfusions, adjusted for within‐patient correlations. A donor‐to‐patient match was categorized as a split‐match if all donor HLA‐A and ‐B antigens were present in the patient as well; that is, donor and patient were HLA identical or compatible. Subgroup analyses were performed for patients with positive or negative HLA antibody screens. Finally, the additional effect of ABO mismatches on 1hCCIs was investigated.RESULTS: The 1hCCI after an HLA‐matched transfusion was 14.09 (95% reference interval, 1.13‐29.89). This was 1.94 (95% confidence interval [CI], 0.74‐3.15) higher than 1hCCI after HLA‐mismatched transfusions. In patients with negative HLA antibody screening tests, HLA matching did not affect 1hCCIs. Conditional on HLA matching, 1hCCIs decreased by 3.70 (95% CI, ‐5.22 to −2.18) with major ABO mismatches.CONCLUSION: Matched platelet concentrates yielded maximal 1hCCIs, whereas mismatched transfusions still resulted in adequate increments. There is no indication for HLA‐matched platelets in patients with negative antibody screens.


  • Bacterial safety of blood components–a congress review of the ISBT transfusion‐transmitted infectious diseases working party, bacterial subgroup

    by Sandra Ramirez‐Arcos, Carl McDonald, Parampal Deol, Aukje L. Kreuger, Nidhi Patel, Heather Pidcoke, Marcel Prax, Axel Seltsam, Adonis Stassinopoulos, The Isbt Transfusion‐Transmitted Infectious Diseases Working Party Subgroup On Bacteria

    The ISBT Working Party on Transfusion‐Transmitted Infectious Diseases, Bacterial Subgroup (TTID‐WP‐BS) held a meeting during the 2017 ISBT Congress covering topics on safety of platelet components (PC), which are highlighted in this review. The TTID‐WP‐BS along with the Paul Ehrlich Institute have pioneered the development of bacterial strain repositories for PC and red blood cells (RBC) to be used for the validation of detection and pathogen reduction (PR) technologies. Results of the development of the RBC repository strains indicated that six bacterial strains were selected for further testing in international studies, complementing the previous study developed for PC. The THERAFLEX UV‐Platelets PR technology has used the bacterial strain repository for PC to test the effectiveness of the system with data presented in this report. Other PR studies described herein include a report of inactivation of Serratia marcescens by the INTERCEPT Blood System for PC at the levels of the PR claim. Furthermore, a summary of current and future developments of the Mirasol PR system was presented with emphasis on PR in whole blood. Advances in PC screening for bacterial contamination were covered by a comparative study of the BacT/ALERT 3D and BacT/ALERT VIRTUO systems, demonstrating that the latter has a shorter time to detection. Finally, data on septic transfusion reactions involving PC produced in plasma and platelet additive solutions indicated different clinical outcomes and screening results. The topics covered during the TTID‐WP‐BS meeting generated insightful scientific discussions and advanced knowledge, one of the most relevant activities of the Bacterial Subgroup.


  • The quality of platelet concentrates related to corrected count increment: linking in vitro to in vivo

    by Anno Saris, Aukje L. Kreuger, Anja Ten Brinke, Jean Louis H. Kerkhoffs, Rutger A. Middelburg, Jaap Jan Zwaginga, Pieter F. van der Meer

    BACKGROUND: Storage of platelet concentrates (PCs) results in reduced recovery and survival of transfused platelets (PLTs). Upon storage PLTs develop storage lesion that can be monitored by several laboratory tests. However, correlation of these descriptive tests with corrected count increments (CCIs), a marker frequently used to establish the effectiveness of PLT transfusions, is limited or unknown. This study investigated to what extent a functional test or a combined in vitro rating score improves the correlation of laboratory tests with 1-hour CCI. STUDY DESIGN AND METHODS: PCs were analyzed using six different laboratory tests (n = 123) before transfusion in a prophylactic setting to 74 hematooncologic patients. Linear regression and Spearman correlation were used to determine associations between descriptive (either separately or combined in an in vitro rating score) or functional test results and 1-hour CCIs obtained after transfusion. RESULTS: CD62P expression (r = -0.45), annexin V binding (r = -0.36), the updated in vitro rating score (r = 0.50), and PLT responsiveness after thrombin receptor activator for peptide-6 (TRAP) (r = 0.43-0.57) or adenosine diphosphate stimulation (r = 0.11-0.51) significantly correlated to 1-hour CCIs obtained after transfusion, whereas lactate concentration, ThromboLUX score, and thromboelastography measurements did not. The strongest correlations were observed for in vitro rating score and PLT responsiveness after TRAP stimulation and these tests could explain 24 and 33% of the observed variation in 1-hour CCI, respectively. CONCLUSION: Combining descriptive markers in one in vitro rating score improved correlation to 1-hour CCI compared to the tests separately. Of all tests investigated, mean PLT responsiveness after TRAP stimulation showed the strongest clinical correlation and was best able to predict the 1-hour CCI.


  • Open Access

    The identification of cases of major hemorrhage during hospitalization in patients with acute leukemia using routinely recorded healthcare data

    by Aukje L. Kreuger, Rutger A. Middelburg, Erik A. M. Beckers, Karen M. K. de Vooght, Jaap Jan Zwaginga, Jean-Louis H. Kerkhoffs, Johanna G. van der Bom

    Electronic health care data offers the opportunity to study rare events, although detecting these events in large datasets remains difficult. We aimed to develop a model to identify leukemia patients with major hemorrhages within routinely recorded health records. The model was developed using routinely recorded health records of a cohort of leukemia patients admitted to an academic hospital in the Netherlands between June 2011 and December 2015. Major hemorrhage was assessed by chart review. The model comprised CT-brain, hemoglobin drop, and transfusion need within 24 hours for which the best discriminating cut off values were taken. External validation was performed within a cohort of two other academic hospitals. The derivation cohort consisted of 255 patients, 10,638 hospitalization days, of which chart review was performed for 353 days. The incidence of major hemorrhage was 0.22 per 100 days in hospital. The model consisted of CT-brain (yes/no), hemoglobin drop of ≥0.8 g/dl and transfusion of ≥6 units. The C-statistic was 0.988 (CI 0.981–0.995). In the external validation cohort of 436 patients (19,188 days), the incidence of major hemorrhage was 0.46 per 100 hospitalization days and the C-statistic was 0.975 (CI 0.970–0.980). Presence of at least one indicator had a sensitivity of 100% (CI 95.8–100) and a specificity of 90.7% (CI 90.2–91.1). The number of days to screen to find one case decreased from 217.4 to 23.6. A model based on information on CT-brain, hemoglobin drop and need of transfusions can accurately identify cases of major hemorrhage within routinely recorded health records.


  • Storage time of platelet concentrates and risk of a positive blood culture: a nationwide cohort study

    by Aukje L. Kreuger, Klaus Rostgaard, Rutger A. Middelburg, Jean‐Louis H. Kerkhoffs, Gustav Edgren, Christian Erikstrup, Ole B. Pedersen, Kjell Titlestad, Kaspar R. Nielsen, Sisse R. Ostrowski, et al.

    BACKGROUND: Concern of transfusion‐transmitted bacterial infections has been the major hurdle to extend shelf life of platelet (PLT) concentrates. We aimed to investigate the association between storage time and risk of positive blood cultures at different times after transfusion.STUDY DESIGN AND METHODS: We performed a nationwide cohort study among PLT transfusion recipients in Denmark between 2010 and 2012, as recorded in the Scandinavian Donations and Transfusions (SCANDAT2) database. Linking with a nationwide database on blood cultures (MiBa), we compared the incidence of a positive blood culture among recipients of PLTs stored 6 to 7 days (old) to those receiving fresh PLTs (1‐5 days), using Poisson regression models. We considered cumulative exposures in windows of 1, 3, 5, and 7 days.RESULTS: A total of 9776 patients received 66,101 PLT transfusions. The incidence rate ratio (IRR) of a positive blood culture the day after transfusion of at least one old PLT concentrate was 0.77 (95% confidence interval [CI], 0.54‐1.09) compared to transfusion of fresh PLT concentrates. The incidence rate of a positive blood culture was lower the day after receiving one old compared to one fresh PLT concentrate (IRR, 0.57; 95% CI, 0.37‐0.87). Three, 5, or 7 days after transfusion, storage time was not associated with the risk of a positive blood culture.CONCLUSION: Storage of buffy coat–derived PLT concentrates in PAS‐C up to 7 days seems safe regarding the risk of a positive blood culture. If anything, transfusion of a single old PLT concentrate may decrease this risk the following day.


  • The effect of World Blood Donor Day on digital information seeking and donor recruitment

    by Floris J. Kranenburg, Aukje L. Kreuger, M. Sesmu Arbous, Daphne Laeijendecker, Marian G.J. van Kraaij

    BACKGROUND: The purpose of World Blood Donor Day (WBDD) is to raise awareness for the importance of blood donation. The aim of this study was to quantify the impact of WBDD on digital information seeking and donor recruitment.STUDY DESIGN AND METHODS: Google Trends data were used to quantify seeking behavior on “blood donation” and “blood donor.” Differences in relative search volume (RSV) between the 3 weeks surrounding WBDD and the rest of the year were calculated. Second, mean differences in RSV were compared to assess the additional effect of hosting using translated search terms. Third, we compared the period around WBDD with the control period regarding page views of the Sanquin website and Facebook likes and number of newly registered donors in 2016.RESULTS: The mean RSV for “blood donation” in the period of interest was 78.6, compared to 72.1 in the control period (difference, 6.5; 95% confidence interval [95% CI], 1.2‐11.8). For “blood donor” this was 78.9 compared to 65.9 (difference, 12.9; 95% CI, 8.1‐17.8). We found no additional effect of hosting. In the period of interest, the website of Sanquin was visited 6862 times a day and 4293 times in the control period (difference, 2569; 95% CI, 1687‐3451). In June 2016, 54.6% (95% CI, 53.0‐56.2) more new donors were registered compared to the control period.CONCLUSION: An international campaign like WBDD raises the awareness of blood donation and is effective in convincing people to register as blood donors.


  • Storage time of platelet concentrates and all‐cause bacteremia in hematologic patients

    by Aukje L. Kreuger, Rutger A. Middelburg, Cock M.C. Bank, Erik A.M. Beckers, Adriaan J. van Gammeren, Anja Leyte, Jan M.M. Rondeel, Karen M.K. de Vooght, Floor Weerkamp, Jaap Jan Zwaginga, et al.

    BACKGROUND: Extension of storage time of platelet (PLT) concentrates may result in an increased risk of bacteremia, directly via transfusion of contaminated products or indirectly via transfusion‐related immunomodulation. We aimed to quantify the association of storage time of PLT concentrates and all‐cause bacteremia in hematologic patients.STUDY DESIGN AND METHODS: We established a cohort of hematologic patients who received a PLT transfusion between 2005 and 2015. Cases were defined as patients with a bacteremia the day after transfusion and matched to as many controls as possible. A conditional logistic regression was performed, stratified by storage medium.RESULTS: Among 3514 patients receiving 36,032 PLT concentrates stored in plasma, 613 cases of bacteremia were found. The relative risk of all‐cause bacteremia the day after transfusion was 0.80 (95% confidence interval [CI], 0.58‐1.12) for PLT concentrates stored 3 to 4 days and 0.67 (95% CI, 0.49‐0.92) for at least 5 days, compared to no more than 2 days. Among 1527 patients receiving 11,822 PLT concentrates stored in PLT additive solution, 182 cases of bacteremia were found. The relative risk of all‐cause bacteremia was 1.14 (95% CI, 0.70‐1.84) for PLT concentrates stored for 3 to 4 days and 1.19 (95% CI, 0.70‐2.01) for at least 5 days, compared to not more than 2 days.CONCLUSION: Storage time of PLT concentrates was not associated with increased occurrence of all‐cause bacteremia the day after transfusion. If anything, fewer cases of bacteremia occurred with increasing storage time of PLT concentrates in plasma. These bacteremias are not directly caused by transfusion of a contaminated product and the underlying mechanism warrants further research.